Butorphanol

Revisión del 23:03 26 ene 2019 de ClaireLewis (discusión | contribs.) (Created page with "==Administration== *Type: synthetic mixed agonist-antagonist opioid *Dosage Forms: *Routes of Administration: IV, IN *Common Trade Names: ==Adult Dosing== *0.5-2mg IV, I...")
(difs.) ← Revisión anterior | Revisión actual (difs.) | Revisión siguiente → (difs.)

Administration

  • Type: synthetic mixed agonist-antagonist opioid
  • Dosage Forms:
  • Routes of Administration: IV, IN
  • Common Trade Names:

Adult Dosing

  • 0.5-2mg IV, IM, or IN q3h prn

Pediatric Dosing

Special Populations

Pregnancy Rating

  • Category C

Lactation risk

  • Infant risk cannot be ruled out

Renal Dosing

  • Reduce dose (0.5-1mg)

Hepatic Dosing

  • Reduce dose (0.5-1mg)

Contraindications

  • Allergy to class/drug
  • Significant respiratory depression
  • Acute or severe asthma if unmonitored setting
  • Known or suspected SBO or ileus

Adverse Reactions

Serious

  • Respiratory depression

Common

Pharmacology

  • Half-life: 4-6h in healthy patients, 10-17h inhepatic or renal impairment
  • Metabolism: Hepatic
  • Excretion: Mostly renal

Mechanism of Action

  • Mixed agonist-antagonist analgesic, kappa-opioid receptor agonist, low intrinsic activity at mu-opioid receptor

Comments

See Also

References

Authors: